IL3RA and neoplasm: As a compromise, it was proposed to use CAR T cells directed against CD123 or CD117 to purge tumor cells and HSCs alike, followed by myeloablative conditioning to remove the CAR T cells before HSCT (Arai et al., 2018; Gill et al., 2014; Myburgh et al., 2020).